ScoreWhy is Glenmark Pharmaceuticals Ltd. ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.89 times
2
With a growth in Net Profit of 1199.62%, the company declared Outstanding results in Sep 25
- ROCE(HY) Highest at 35.65%
- OPERATING PROFIT TO INTEREST(Q) Highest at 35.50 times
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 2,690.24 cr
3
With ROE of 23.5, it has a Attractive valuation with a 5.8 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 27.86%, its profits have risen by 554.2% ; the PEG ratio of the company is 0
4
High Institutional Holdings at 39.38%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 1.08% over the previous quarter.
5
Consistent Returns over the last 3 years
- Along with generating 27.86% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Glenmark Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Glenmark Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Glenmark Pharma
39.14%
0.88
31.53%
Sensex
8.49%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.70%
EBIT Growth (5y)
19.50%
EBIT to Interest (avg)
6.97
Debt to EBITDA (avg)
1.60
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
1.06
Tax Ratio
33.64%
Dividend Payout Ratio
6.74%
Pledged Shares
0
Institutional Holding
39.33%
ROCE (avg)
16.69%
ROE (avg)
10.68%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
23
Industry P/E
32
Price to Book Value
5.78
EV to EBIT
14.10
EV to EBITDA
12.33
EV to Capital Employed
6.64
EV to Sales
3.27
PEG Ratio
0.03
Dividend Yield
0.26%
ROCE (Latest)
44.14%
ROE (Latest)
23.46%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
NET SALES(Latest six months)
At Rs 9,947.49 cr has Grown at 45.83%
PAT(Latest six months)
Higher at Rs 2,026.77 cr
ROCE(HY)
Highest at 35.65%
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 2,690.24 cr
DEBT-EQUITY RATIO(HY)
Lowest at 0.13 times
-3What is not working for the Company
PBT LESS OI(Q)
At Rs 673.87 cr has Fallen at -19.3% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Glenmark Pharma
Profit After Tax (PAT) - Latest six months
At Rs 2,026.77 cr has Grown at 188.64%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 9,947.49 cr has Grown at 45.83%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 2,026.77 cr
than preceding 12 month period ended Dec 2025 of Rs 1,117.42 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 2,690.24 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio - Half Yearly
Lowest at 0.13 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Glenmark Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 673.87 cr has Fallen at -19.3% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 834.64 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
